Journals By Industry - Protein Based Drugs

GS-7340 is a novel prodrug of tenofovir, the active agent in Viread, or tenofovir disoproxil fumarate. In previous studies, GS-7340 has demonstrated the ability to provide greater antiviral efficacy at a dose that...

Stony Brook University has entered into a multiyear research partnership with the global pharmaceutical company Sanofi to develop a potential treatment for tuberculosis and other bacterial infections. The university didn't disclose the terms...

RESEARCH TRIANGLE PARK, N.C. -- BioCryst Pharmaceuticals, Inc., (NASDAQ:BCRX) today announced that Nancy J. Hutson, Ph.D. was elected to the Company's Board of Directors, effective Friday, January 20, 2012. "We are excited to...

NEEDHAM, Mass. -- Celldex Therapeutics, Inc. (Nasdaq: CLDX) today announced that it will host a research and development day for the investment community on Monday, January 23, 2012 at 8:30 am Eastern Time....

NEWTOWN, Pa. -- Quotient Biodiagnostics, Inc. (Quotient), a supplier of innovative and high-quality transfusion diagnostic products to hospitals, blood banks and other healthcare institutions, is pleased to announce that its range of ALBAcyte[R]...

Study also Demonstrated 100% Sustained Virologic Response 12-Weeks Post Treatment with Quadruple Therapy Phase II Investigational Data Published Today in the New England Journal of Medicine PRINCETON, N.J. -- Bristol-Myers Squibb Company (NYSE:...

JENA, Germany -- InflaRx announced today the successful completion of its recent clinical phase I study investigating its lead drug candidate IFX-1, a new first in class monoclonal antibody inhibiting complement driven inflammation....

Professors David Kerr and Nick La Thangue offer oncology consulting and biomarker R&D activities spun out from the University of Oxford OXFORD, U.K. & RESEARCH TRIANGLE PARK, N.C. -- Continuing its commitment to...

WALTHAM, Mass. -- ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted antibody-based anticancer products, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, January...

According to Pfizer and Medivation, Dimebon (latrepirdine) failed to meet either of its co-primary endpoints in the Phase III trial. Over the course of 12 months, no statistically significant improvements were noted on...

CAMBRIDGE, Mass. -- Constellation Pharmaceuticals, Inc., today announced that it has entered into a major strategic agreement with Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), to launch a...

NEEDHAM, Mass. -- Celldex Therapeutics, Inc. (Nasdaq: CLDX) today announced that dosing has initiated in a Phase 1 study of its hematopoietic growth factor, CDX-301, in healthy subjects. The study is being conducted...

* Closed approximately $630.0 million in Commitments in 2011, up 20% Year-over-Year * Closed approximately $165.0 million in Commitments to new and existing portfolio companies in the Fourth Quarter * Entered into an...

DUBLIN -- Research and Markets (http://www.researchandmarkets.com/research/dd25b8/bsl3_and_bsl4_agen) has announced the addition of John Wiley and Sons Ltd's new book "BSL3 and BSL4 Agents: Proteomics, Glycomics, and Antigenicity" to their offering. Edited by leading experts...

Dimebon Did Not Meet Primary Efficacy Endpoints SAN FRANCISCO & NEW YORK -- Medivation, Inc.(NASDAQ: MDVN) and Pfizer Inc. (NYSE: PFE) today announced results from the CONCERT trial, which is a Phase 3...

BERLIN -- JPT Peptide Technologies GmbH (JPT), a wholly-owned subsidiary of BioNTech AG (Mainz, Germany), IUCT and LEITAT (Barcelona, Spain) announced today their collaboration on the joint development of an enhanced anticancer therapy...

BOULDER, Colo. -- Array BioPharma Inc. (NASDAQ: ARRY) today announced that Robert E. Conway has resigned as Chief Executive Officer and a Director for personal reasons. The Board has appointed Kyle Lefkoff, Chairman...

Cold adapted and heat-labile unique Enzymes that Improve Molecular Biology TROMSO, Norway -- ArcticZymes AS announced today the formation of ArcticZymes Inc. a wholly owned subsidiary located in Plymouth Meeting, PA. The Company...

HALLE, Germany -- Scil Proteins, a private biotech company specialized in the research, development and production of recombinant proteins, announced today that it has signed a supply agreement with Actavis, one of the...